Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling are established contributors to malignant glioma (MG) biology. We, therefore, evaluated bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination with the EGFR tyrosine kinase inhibitor erlot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sathornsumetee, Sith, Desjardins, Annick, Vredenburgh, James J., McLendon, Roger E., Marcello, Jennifer, Herndon, James E., Mathe, Alyssa, Hamilton, Marta, Rich, Jeremy N., Norfleet, Julie A., Gururangan, Sridharan, Friedman, Henry S., Reardon, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2010
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3018944/
https://ncbi.nlm.nih.gov/pubmed/20716591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noq099
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados